HR 1843
To amend the Federal Food, Drug, and Cosmetic Act to increase transparency in generic drug applications.
Jurisdiction
US Congress
Session
119th Congress (2025-2026)
Last updated at
Jun 14, 2026, 4:34 AM
Take action
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take action- Introduced
- Passed House
- Passed Senate
- To President
- Became Law
Bill overview
This bill aims to increase transparency in the process of approving generic drugs. It requires the Food and Drug Administration (FDA) to inform applicants whether a generic drug is the same as the brand-name drug it’s copying, and if not, to explain the differences. The FDA will also create and update guidance on how it makes these determinations, ensuring clarity for drug manufacturers. This increased transparency is intended to improve the efficiency and predictability of the generic drug approval process.
Sponsors
Official sponsors from legislative records.
Primary sponsor
Cosponsor
Arguments in favor
Reasons to support this legislation.
No arguments in favor have been submitted.
Submit yoursArguments opposed
Reasons to oppose this legislation.
No arguments opposed have been submitted.
Submit yoursRead the latest version inline or switch to a previous version.